Background: Oral methadone is considered to be a valid opioid analgesic alternative to morphine and hydromorphone in treating cancer pain. However, the use of methadone could be complicated by the limited knowledge of the equianalgesic dose/ratio with the other analgesic opioids when switching in tolerant patients.
Introduction
According to the World Health Organization [1] , opioid analgesics are the mainstay of therapy for cancer-related pain. In treating cancer patients with pain, the type of opiod analgesic and/or the route of administration often needs to be changed more than once because of modification of the clinical situation, the presence of unwanted drug-related side effects or escalating drug doses that are required [2] [3] [4] [5] [6] [7] [8] .
Oral methadone may be considered an ideal alternative drug for opioid switching due to its high oral bioavailability, analgesic efficacy, no known active metabolites, low cost, the lower number of daily administrations in respect to other opioid agonist analgesics [9] [10] [11] [12] . Unfortunately, the use of methadone could be complicated by the long and unpredictable half-life, large inter-individual variations in pharmacokinetics, and, above all, by the limited knowledge of the equianalgesic dose/ratio with the other analgesic opioids when switching in tolerant patients [10] .
When a change in the type of opioid is considered, the dose is titrated according to the indications of the equianalgesic tables. Some of these tables propose a dose ratio of 1:1 between oral morphine and oral methadone [13, 14] and parenteral morphine and parenteral methadone [15, 16] . Other equianalgesic tables propose a morphine-methadone ratio of 4:1 for the oral route and 2.7:1 for the parenteral route [17] . In the case of subcutaneous hydromorphone to methadone, tables propose dose ratios ranging from 1: 6 to 1:10 [13, 15, 17] .
From clinical experience and recent data in literature, methadone appears to be a much more potent analgesic than previously described and with an equianalgesic dose/ratio varying according to the previous opioid dose administered to the patients [18, 19] . However, these findings and the observation of occasional severe toxicity when switching to oral methadone [20] might not apply to patients on lower opioid dosages. A recent study from Milan found no serious toxicity in 196 cancer patients who received oral methadone [11] .
The aims of this retrospective study were: (1) to determine the equianalgesic dose ratio between oral methadone and other opioid agonists, (2) to compare two different cohort of patients with a very different exposure to opioid analgesics before switching to oral methadone and verify the equianalgesic dose/ratio in relation to the dose of opioid previously administered.
Patients and methods
Data collected, regarding 88 advanced cancer patients with pain who switched from different opioids to oral methadone, were reviewed.
Fifty-one out-patients were followed at the PCU, Milan National Cancer Institute, from August 1995 until February 1996.
From a total of 65 patients [19] admitted to the Palliative Care Unit (PCU), Edmonton General Hospital, we considered only those 37 patients who switched from subcutaneous hydromorphone to oral methadone.
In both centers patients were switched to oral methadone from another opioid by a specialist in cancer pain treatment. In both groups the following information was collected from the charts: (A) before switching: (1) age, gender, primary diagnosis, (2) type of opioid administered, (3) previous final dose of opioid before the rotation reported in equivalent daily dose (EDD) of parenteral hydromorphone, (4) pain intensity, (5) reasons for switching to methadone; (B) after switching: (1) stabilization dose or steady state analgesic dose of oral methadone (need for an increase in dose of less than 20% for at least 48 h), (2) pain intensity at the stabilization dose, (3) discontinuation of oral methadone due to analgesic inefficacy or due to unwanted side effects (that is, the symptoms that the patient referred as being directly associated with the administration of methadone and for which the patient or the doctor requested the suspension of treatment).
Analgesia was evaluated by Visual Analogue Scale (VAS) (0 = no pain; 100 = worst possible pain) at the Edmonton PCU and by the Integrated Pain Score (IPS) [21] at the Milan PCU (data are not collected by the treating clinician).
The integrated pain score is a way of evaluating pain, as it integrates the intensity and duration of pain into a single score. By using five key words: slight, moderate or troublesome, severe or exhausting, terrible, excruciating or 'killing', a patient can describe the pain intensity for the preceding 24 hours. The exact value to be attributed to these key words has already been established numerically. In order to obtain a daily pain score, the hours of pain (defined by each key word) are multiplied by a corresponding factor: slight = 1; troublesome = 2.5; exhausting = 5; terrible = 7.5; excruciating = 10 and then totalled. According to this method, the obtainable scores range from 0 to 240. This number, which we call the 'integrated pain score', can be easily and quickly totalled.
De Conno et al. [22] showed that there is a close statistical correlation between a daily IPS and a daily VAS.
Data analysis
Data were analyzed separately for each PCU and also in association. Pearson and Spearman correlations were used for the correlations between variables such as previous opioid dose, stable dose of oral methadone and dose ratios for the Edmonton Group, Milan Group and combined data. Unpaired ?-test was used for the comparison of parametric data and chi-square test was used for the comparison of proportions. Data was analyzed according to the SAS system for personal computer [23] . Table 1 shows the characteristics of the patients under study and the previous opioid treatment before switching. All the patients in Edmonton were being treated with parenteral hydromorphone, whereas, the patients in Milan were treated with different opioids and the median total equivalent parenteral hydromorphone dose before the opioid change was calculated. In the patients treated in Milan, the reasons of the switch to methadone were: placing the nasogastric tube for feeding (11 patients) and then the need to use an opioid in solution form (at the moment methadone is the only opioid analgesic available in solution form in Italy); poor pain control at dose limiting toxicity of the previous opioid (30 patients); difficulty in swallowing (10 patients). In the Edmonton group, the reasons for opioid switch were: poor pain control at dose limiting toxicity of the previous opioid (31 patients), and development of toxicity in good pain control (6 patients). Table 2 summarizes the previous dose of opioid, new stable dose, dose ratio and pain intensity for the Edmonton group, the Milan group and the combined group of 88 patients. The dose ratio hydromorphone/methadone was 1.47 (0.81-2.47) for the Edmonton group, 0.25 (0.17-0.44) for the Milan group and 0.51 (0.20-1.38) for the combined group.
Results
In the Edmonton group, the value was approximately five to 15 times higher than as suggested by equianalgesic tables [13, 15, 17] and the value of the Milan group was approximately one to five times higher. Table 3 shows the equianalgesic dose ratio hydromorphone/methadone at different levels of opioid exposure. It is possible to see that the dose ratio was higher when patients were receiving higher doses before switchover. Figure 1 shows the correlation between the final hydromorphone dose (mg/day) and the hydromorphone/ methadone ratio in all the patients under study.
No patients presented unwanted side effects that necessitated methadone discontinuation.
Discussion
In this retrospective study, we reviewed and compared the results of switching from different opioids (expressed as equivalent parenteral hydromorphone) into oral methadone in 88 advanced patients with cancer-related pain at two different Palliative Care Units. Considering that two different PCU are involved, the comparison is Abbreviations: HM -parental hydromorphone; ME -oral methadone. P < 0.001 for the overall difference. a Data expressed as median (lower and upper quartiles). important. The main differences between both centers is in the total opioid dose taken by the patients before opioid switching. While most of the out-patients in Milan were opioid-naive at the first visit and had been started on opioids at the PCU less than a month before switching to oral methadone, the Edmonton in-patients had been exposed to high opioid dosage for a long time before referral, and so before switching. The combined group made it possible to evaluate equianalgesic ratio over a variety of opioid dosages. Since all patients had similar pain syndromes and were treated by highly experienced physicians using similar criteria, the most likely reason for the large difference in opioid dose between groups is the length of patient exposure to opioids. In similar studies tolerance developed over time after opioid administration. In humans, this issue is controversial [24] . Future prospective studies should address the possibility of tolerance development over time to opioid agonists. For all patients, the switchover to oral methadone was done for clinical reasons. For 61 of all patients under evaluation, the reason for opioid switching was the development of dose limiting opioid toxicity, with or without adequate analgesia. This might be considered a limitation for accurately estimating dose ratios. However, in the clinical setting, patients will rarely undergo opioid switching while in good pain control and with no side effects. Rather, most patients are switched from one opioid to another due to side effects and insufficient analgesia and, therefore, our observations are applicable.
Our findings suggest that there is a significant differ-ence in the dose ratio between the Edmonton group and the Milan group. However, for each of the two groups of patients there was a highly significant association between previous opioid exposure and methadone ratio. The result from Milan confirms the hypothesis that patients previously exposed to lower opioid doses require relatively higher doses of methadone in order to achieve analgesic effect [19] . The finding in the two groups of patients and in the combined cohort are consistent with the following factors: (1) methadone displays incomplete cross-tolerance with other mu-opioids; (2) methadone is a mu-delta opioid agonist and hydromorphone is probably essentially just a mu-agonist and therefore the doses of methadone would be smaller than expected in patients who had been made at least partly tolerant to hydromorphone by escalation of the dose to very high levels; (3) methadone differs from hydromorphone because of a non-competitive antagonist activity at the N-methyl-D-aspartate (NMDA) receptor [25, 26] , this non-opioid NMDA receptor antagonism may reduce the development of tolerance. For one or more of these reasons methadone is more potent than believed and even more potent in patients tolerant to high hydromorphone doses.
In both the Edmonton and Milan groups, oral methadone was able to achieve equal or superior analgesia as compared to hydromorphone (as demonstrated by pain intensity scales, Table 2 ) and at doses lower than expected. It confirms a previous observation [18] suggesting that methadone is much more potent than has been presented in equianalgesic tables. However, there is a wide ratio range which suggests that pharmacological titration or the process of dose finding should be individualized and carried out by experts in the field.
The fact that methadone ratio is different according to the opioid dose used previously should be taken into careful consideration by the clinician in order to avoid severe toxicity or death during switchover.
The results of our study should lead to carry out prospective, properly designed studies to evaluate the equianalgesia of different opioid drugs and to review the current equianalgesic tables taking into consideration that many of the data regarding ratios are relative to acute studies and not to chronic studies as necessary in patients with cancer pain.
